STRATEC SE (Frankfurt: SBS; Prime Standard) held its Annual General Meeting on June 23, 2026, where shareholders approved all agenda items with clear majorities. The company will distribute a dividend of EUR 0.60 per share for the 2024 financial year, matching the previous year's dividend. The total distribution amounts to EUR 7.3 million, payable to shareholders via their depositing banks on June 26, 2026.
Shareholders also ratified the actions of the Board of Management and the Supervisory Board, elected PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (PwC), Frankfurt am Main, as the auditor for the 2026 financial year, and approved the remuneration report. The meeting saw 70.1 percent of the company's registered share capital represented.
STRATEC SE designs and manufactures fully automated analyzer systems for partners in clinical diagnostics and life sciences, as well as complex consumables for diagnostic and medical applications. The company covers the entire value chain from development to production and quality assurance. Its partners market the systems, software, and consumables, often alongside their own reagents, to laboratories, blood banks, and research institutes worldwide. STRATEC develops its products based on patented technologies.
The dividend approval reflects STRATEC's commitment to sharing its financial performance with shareholders, providing a stable return even as the company invests in innovation and growth. For leaders in business and technology, this signals confidence in the company's ongoing operations and its ability to generate consistent cash flow. The continued dividend payout may be seen as a positive indicator for investors considering the diagnostics and life sciences automation sector.
Further details on the Annual General Meeting, including voting results, are available at www.stratec.com/agm. STRATEC SE shares are traded in the Prime Standard segment of the Frankfurt Stock Exchange under ISIN DE000STRA555.
This development matters because it demonstrates corporate governance stability and shareholder value focus, which are key considerations for institutional investors and industry observers monitoring the automation technology space in healthcare.
